Keros Therapeutics (KROS) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Keros Therapeutics (KROS) over the past year, gaining 43.0% versus a loss of 22.9%. Over five years, KROS leads with a -72.5% price change compared with -97.3% for ZNTL. Keros Therapeutics is the larger company by market cap ($211.4 million vs $209.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | ZNTL |
|---|---|---|
| Share price | $10.66 | $2.13 |
| Market cap | $211.36M | $209.00M |
| 1-day change | -3.96% | -4.91% |
| YTD return | -47.64% | +57.78% |
| 1-year return | -22.92% | +42.95% |
| 5-year return | -72.54% | -97.27% |
| EPS (TTM) | $-3.22 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $243.86M | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $87.01M | $-137.06M |
| Operating margin | 27.71% | — |
| Net margin | 35.68% | — |
| 52-week high | $22.55 | $6.95 |
| 52-week low | $9.69 | $1.21 |
| Distance from 52-week high | -52.73% | -69.35% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +86.02% | +249.30% |
| Average volume | 189.85K | 1.17M |
| Shares outstanding | 19.83M | 98.12M |
| Employees | 92 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed KROS by 65.9 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
KROS vs ZNTL FAQ
Which is bigger, Keros Therapeutics or Zentalis Pharmaceuticals?
Keros Therapeutics (KROS) is larger, with a market capitalization of $211.36M compared with $209.00M for Zentalis Pharmaceuticals (ZNTL).
Which stock has performed better over the past year, KROS or ZNTL?
ZNTL returned +42.95% over the past 12 months, compared with -22.92% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.